Ocular Implants Technology for Ocular Hypertension and Glaucoma - Medical / Health Care - Clinical Services
Ocular Hypertension is defined as elevated intraocular pressure (IOP) without ocular damage and is associated with an increased risk of progression to Glaucoma.1,2 Nearly 7 million adults over the age of 40 in the US are estimated to suffer from Ocular Hypertension. 1,3
Most popular related searches
Glaucoma is a chronic progressive disease characterized by elevated IOP with progressive optic nerve damage, retinal nerve fiber layer defects and visual field loss. 90% of Glaucoma cases are classified as Open-Angle Glaucoma based on a normal angle between the iris and cornea.4 Nearly 3 million adults in the US suffer from Open-Angle Glaucoma and is the leading cause of blindness.1,3,5 Nearly 50% of Glaucoma patients go undiagnosed since the disease is asymptomatic in the early stages.6 The damage caused by Glaucoma cannot be reversed, but treatment can slow or prevent vision loss.
Although eye drops are the first line therapy, correct patient administration is difficult and the ability to do so worsens with age, comorbidities, and disease progression. Eye drops also cause side effects including redness of the white of the eye (hyperemia) and eye surface changes. As a result, poor adherence and compliance is a commonly cited reason for treatment failure with rates of 30-50% causing persistence of Glaucoma in up to 64% of cases.7
There is a need for a safe biodegradable, sustained-release treatment that effectively reduces IOP, is well tolerated by patients and provides a constant drug dose with a predictable degradation profile.